Patent Assignment
Reel/Frame 070551/0120
Release of Security Interest in Patent Collateral
Recorded: 2025-03-05
Pages: 14
Assignor
BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Executed: 2025-02-28
Assignees
BRIDGEBIO PHARMA, INC.
3160 PORTER DRIVE, SUITE 250, PALO ALTO, CALIFORNIA, 94304
QED THERAPEUTICS, INC.
3160 PORTER DRIVE, SUITE 250, PALO ALTO, CALIFORNIA, 94304
EIDOS THERAPEUTICS, INC.
3160 PORTER DRIVE, SUITE 250, PALO ALTO, CALIFORNIA, 94304
ML BIO SOLUTIONS INC.
3160 PORTER DRIVE, SUITE 250, PALO ALTO, CALIFORNIA, 94304
NAVIRE PHARMA, INC.
3160 PORTER DRIVE, SUITE 250, PALO ALTO, CALIFORNIA, 94304
CANTERO THERAPEUTICS, INC.
3160 PORTER DRIVE, SUITE 250, PALO ALTO, CALIFORNIA, 94304
BRIDGEBIO GENE THERAPY RESEARCH, INC.
3160 PORTER DRIVE, SUITE 250, PALO ALTO, CALIFORNIA, 94304
FERRO THERAPEUTICS, INC.
3160 PORTER DRIVE, SUITE 250, PALO ALTO, CALIFORNIA, 94304
BRIDGEBIO SERVICES INC.
3160 PORTER DRIVE, SUITE 250, PALO ALTO, CALIFORNIA, 94304
Covered Properties
(11)
Combination Therapy Using Substituted Pyrimidin-4(3H)-Ones and Sotorasib
PCT:
PCT/US2022/045413 ↗
Processes for Preparing Ag-10, Its Intermediates, and Salts Thereof
Application:
18/413,175 →
Publication:
US 2024/0239751
Gene Therapy for Tuberous Sclerosis
Application:
18/570,040 →
Publication:
US 2024/0261439
Gene Therapy for Galactosemia
Application:
18/575,350 →
Publication:
US 2025/0001008
PTPN11 Inhibitors
Application:
18/587,790 →
Deuterated Infigratinib Compounds
Application:
18/599,623 →
Publication:
US 2025/0101002
Assays for Alpha-Dystroglycan Glycosylation and Methods for Using Same
Application:
18/605,744 →
Publication:
US 2024/0369576
Combination Therapy Using a PTPN11 Inhibitor and an Egfr Inhibitor
Application:
18/696,952 →
Publication:
US 2025/0195520
Substituted Pyrimidin-4(3H)-Ones for Use in Treating Cancer
Application:
18/698,694 →
Publication:
US 2025/0213563
1H-1,2,3-Triazole-4-Carboxylic Acids for Treatment of Hyperoxaluria and Kidney Stones
Application:
18/700,172 →
Publication:
US 2024/0423961
Methods and Compositions for Treating Leukodystrophies
Application:
18/700,508 →
Publication:
US 2026/0048146
Related Assignments
(7)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jan 19, 2024
From: SCOTT, DAVID WAYNE
To: BRIDGEBIO GENE THERAPY RESEARCH, INC.
Reel/Frame 066181/0563 →
Assignment of Assignor's Interest
Apr 1, 2024
From: CHAND, POORAN; GUPTA, YOGESH KUMAR; KUMAWAT, RAKESH KUMAR; ALHAMADSHEH, MAMOUN
To: EIDOS THERAPEUTICS, INC.
Reel/Frame 066965/0001 →
Assignment of Assignor's Interest
May 3, 2024
From: BEARD, CLAYTON; CHAPMAN, JULIA NICOLE; MCCOY, DANIEL DAVID
To: BRIDGEBIO GENE THERAPY RESEARCH, INC.
Reel/Frame 067313/0466 →
Assignment of Assignor's Interest
Jun 4, 2024
From: LAFORET, GENEVIEVE; SHAYWITZ, ADAM; KIRBY, KATHLEEN M.
To: BRIDGEBIO SERVICES INC.
Reel/Frame 067608/0887 →
Assignment of Assignor's Interest
Jun 4, 2024
From: BRIDGEBIO SERVICES INC.
To: ASPA THERAPEUTICS, INC.
Reel/Frame 067608/0968 →
Assignment of Assignor's Interest
Jun 4, 2024
From: ASPA THERAPEUTICS, INC.
To: BRIDGEBIO GENE THERAPY LLC
Reel/Frame 067609/0031 →
Security Interest
Jun 28, 2024
From: BRIDGEBIO PHARMA, INC.; EIDOS THERAPEUTICS, INC.; ML BIO SOLUTIONS INC.; NAVIRE PHARMA, INC.
To: BLUE OWL CAPITAL CORPORATION
Reel/Frame 067870/0874 →